Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells

Abstract

One hundred and seventy-seven stem cell apheresis procedures performed on 91 patients using the Fenwal CS 3000 Plus cell separator and 61 procedures performed on 37 patients using the Cobe Spectra cell separator were studied to compare the CD34⁺ cell collection efficiencies (CE; the proportion of the total CD34⁺ cell content in the blood volumes processed that is harvested) of the two machines. The absolute peripheral blood CD34⁺ cell count was comparable for the two groups (P = 0.27). A strong correlation was seen between the blood CD34⁺ cell count and the total number of CD34⁺ cells collected for the Spectra (r² = 0.59; P < 10⁻⁶) and for the CS 3000 Plus (r² = 0.60; P < 10⁻⁶). No significant correlation emerged between the peripheral blood CD34⁺ cell count and the CE of either machine. The total number of CD34⁺ cells collected per procedure was comparable (P = 0.51): median 113 × 10⁶ for CS 3000 Plus and median 218 × 10⁶for Spectra. CE was significantly higher with the Spectra (median 45.7%, range 9.8–98.6%) than the CS 3000 Plus (median 30.3%, range 1.7–89.3%; P < 0.00001). We conclude that the CD34⁺ cell CE of the Spectra is superior to that of the CS 3000 Plus. Therefore, under the usual clinical conditions, Cobe Spectra should be used preferentially for peripheral blood progentor cell collection to maximize the number of hematopoietic stem cells collected.